Sanofi: new indication for Libtayo in the US

(CercleFinance.com) - Sanofi today reports that the US FDA has approved Libtayo for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) in which 50% or more of the tumor cells express the PD-L1 protein.


Patients must have either metastatic or locally advanced cancer, be ineligible for surgical resection or definitive chemoradiotherapy, and their tumours must not express EGFR, ALK or ROS1 aberrations.

The effect of Libtayo on prolonging overall survival was greater than that of chemotherapy in a pivotal trial that took into account disease characteristics that are often underrepresented in clinical trials for advanced NSCLC.


Copyright (c) 2021 CercleFinance.com. All rights reserved.